Lapatinib in gastric cancer: What is the LOGiCal next step?

Journal of Clinical Oncology

Volumn 34, Issue 5, 2016, Pages 401-403

  Janjigian, Yelena Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CAPECITABINE PLUS OXALIPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 17; EDITORIAL; GENE DOSAGE; HUMAN; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; TREATMENT RESPONSE; ADENOCARCINOMA; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL JUNCTION; GENETICS; MALE; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84958984244     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.2892     Document Type: Editorial

References (24)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015
2. Tafe LJ, Janjigian YY, Zaidinski M, et al: Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 135: 1460-1465, 2011
3. Bang YJ, Van Cutsem E, Feyereislova A, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
4. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51, 2007
5. Wainberg ZA, Anghel A, Desai AJ, et al: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16:1509-1519, 2010
6. Iqbal S, Goldman B, Fenoglio-Preiser CM, et al: Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 22:2610-2615, 2011
7. Satoh T, Xu R-H, Chung HC, et al: Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study. J Clin Oncol 32: 2039-2049, 2014
8. Hecht JR, Bang Y-J, Qin SK, et al: Lapatinib in combination with capecitabine plus oxaliplatin in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: (TRIO-013/LOGiC) A randomized phase III trial. J Clin Oncol 34:443-451, 2016
9. Bang Y-J, Van Cutsem E, Lehle M, et al: Trastuzumab for gastric cancer treatment: Authors' reply. Lancet 376:1735-1736, 2010
10. Gomez-Martin C, Plaza JC, Pazo-Cid R, et al: Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 31:4445-4452, 2013
11. Bass AJ, Thorsson V, Shmulevich I, et al: Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209, 2014
12. Janjigian YY, Imtiaz T, Huang X, et al: Patient-derived xenografts as models for the identification of predictive biomarkers in esophagogastric cancer. J Clin Oncol 32:5s, (suppl; abstr 4059), 2014
13. Leto SM, Sassi F, Catalano I, et al: Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-3066 [epub ahead of print on August 21, 2015]
14. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
15. Janjigian YY, Viola-Villegas N, Holland JP, et al: Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med 54:936-943, 2013
16. Gelmon KA, Boyle FM, Kaufman B, et al: Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31. J Clin Oncol 33:1574-1583, 2015
17. Baselga J, Bradbury I, Eidtmann H, et al: NeoALTTO Study Team: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640, 2012
18. Spector NL, Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838-5847, 2009
19. Riemenschneider MJ, Bell DW, Haber DA, Louis DN: Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. N Engl J Med 352: 1724-1725, 2005
20. Janjigian YY, Imtiaz T, Ilson DH, et al: A phase II study of afatinib (A) in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab (T) refractory esophagogastric (EG) cancer. Cancer Res 74, 2014 (abstr CT228) doi:10.1158/1538-7445.AM2014-CT228
21. Kim J, Fox C, Peng S, et al: Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest 124:5145-5158, 2014
22. Leyland-Jones B, Colomer R, Trudeau ME, et al: Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol 28:960-966, 2009
23. Oude Munnink TH, Dijkers EC, Netters SJ, et al: Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J Clin Oncol 28:e355-e356, author reply e357, 2010
24. Cristescu R, Lee J, Nebozhyn M, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 21: 449-456, 2015